BRCA2 and cancer: Dose–response experiments were performed using the BRCA1 and BRCA2 wild-type breast (MDA-MB-231 and MCF-7) and ovarian (HEY-T30 and SKOV-3) cancer cell lines to determine the differences in their drug sensitivity and the concentrations appropriate for the drug combination experiments.